CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lanoix, J.
Right arrow Articles by Skup, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lanoix, J.
Right arrow Articles by Skup, D.

Cell Growth & Differentiation, Vol 2, Issue 8 391-399, Copyright © 1991 by American Association of Cancer Research


ARTICLES

Regulated expression of Krox-24 and other serum-responsive genes during differentiation of P19 embryonal carcinoma cells

J Lanoix, P Belhumeur, M Lussier, A Royal, R Bravo and D Skup
Institut du cancer de Montreal, Quebec, Canada.

In order to identify genes that may play a role in the onset of the differentiation program elicited by retinoic acid, we analyzed, in P19 embryonal carcinoma cells, the expression of genes that are part of the early response of mouse fibroblasts to growth factor stimulation. In this paper, we show that a sequence-specific transcriptional activator, Krox-24, is rapidly induced, under conditions that promote differentiation of P19 cells. Expression of three other serum- and retinoic acid-stimulated genes (clones AC36, C1, and G39) was also studied. Induction of these genes occurs during the first 48 h of exposure of cells to retinoic acid, a period that precedes cell type determination. Our results suggest that different mechanisms regulate the expression of the Krox-24 gene in differentiating P19 cells. A labile repressor seems to be responsible for control of Krox-24 expression in P19 embryonal carcinoma cells. Inactivation of this repressor following retinoic acid treatment resulted in several peaks of activation of the Krox-24 gene, mediated by different mechanisms, some of which did not require de novo protein synthesis. In contrast, activation of AC36 required de novo protein synthesis, and that of C1 and G39 did not. The four genes are differentially expressed in several mouse tissues and during mouse embryonic development.


This article has been cited by other articles:


Home page
J Biol ChemHome page
W. H. Faour, N. Alaaeddine, A. Mancini, Q. W. He, D. Jovanovic, and J. A. Di Battista
Early Growth Response Factor-1 Mediates Prostaglandin E2-dependent Transcriptional Suppression of Cytokine-induced Tumor Necrosis Factor-{alpha} Gene Expression in Human Macrophages and Rheumatoid Arthritis-affected Synovial Fibroblasts
J. Biol. Chem., March 11, 2005; 280(10): 9536 - 9546.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
A. Hollnagel, V. Oehlmann, J. Heymer, U. Rüther, and A. Nordheim
Id Genes Are Direct Targets of Bone Morphogenetic Protein Induction in Embryonic Stem Cells
J. Biol. Chem., July 9, 1999; 274(28): 19838 - 19845.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
S. L. Lee, L. C. Tourtellotte, R. L. Wesselschmidt, and J. Milbrandt
Growth and Differentiation Proceeds Normally in Cells Deficient in the Immediate Early Gene NGFI-A
J. Biol. Chem., April 28, 1995; 270(17): 9971 - 9977.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1991 by the American Association of Cancer Research.